Mergers & Acquisitions ·
Quince Therapeutics completed its acquisition of Orphai Therapeutics on May 17, 2026
QNCXIRulya Therapeutics Inc.
Quince Therapeutics completed its acquisition of Orphai Therapeutics on May 17, 2026. The transaction provided $115 million in upfront gross proceeds, with potential additional proceeds from warrant exercises. Quince acquired Orphai's lead asset, LAM-001, an investigational inhaled dry powder formulation of rapamycin for pulmonary disorders. Key executives Brigette Roberts and Keith Fandrick joined the company. The filing updates financial statements to include Orphai's audited results for 2024 and 2025, interim data for Q1 2026, and pro forma combined financials. Quince Therapeutics is a clinical-stage biopharmaceutical company developing therapies for pulmonary diseases.